Clinical Epidemiology & Biostatistics
Barbara Schmidt
MD (Georg-August), PhD (Georg August), MSc(McMaster), FRCPCProfessor (Part-time), Dept of Clinical Epidemiology & Biostatistics
Associate Editor, ACP Journal Club
905.527.2299 x 43790
905.575.2646
schmidt@mcmaster.ca
Academic Interests
Dr. Barbara Schmidt is a pediatrician and staff neonatologist at the Hamilton Health Sciences. Currently Dr. Schmidt is focusing on large neonatal randomized trials with clinically important long-term outcomes such as growth and development. Apart from her clinical practice in neonatal intensive care and research, Dr. Schmidt is also actively involved in teaching.
Selected Publications
- Barbara Schmidt, M.D., Robin S. Roberts, M.Sc., Peter Davis, M.D., Lex W. Doyle, M.D., Keith J. Barrington, M.D., Arne Ohlsson, M.D., Alfonso Solimano, M.D., Win Tin, M.D., for the Caffeine for Apnea of Prematurity Trial Group. Caffeine Therapy for Apnea of Prematurity. NEJM 2006:354:2112-2121
- Millar, D, Schmidt B. Controversies surrounding xanthine therapy. Seminars in Neonatology 2004, 9:239-244.
- Schmidt B, Asztalos EV, Roberts RS, Robertson CMT, Sauve RS, Whitfield MF for the Trial of Indomethacin Prophylaxis in Preterms Investigators. Impact of Bronchopulmonary Dysplasia, Brain Injury, and Severe Retinopathy on the Outcome of Extremely Low-Birth-Weight Infants at 18 Months. Results From the Trial of Indomethacin Prophylaxis in Preterms. JAMA 2003; 289:1124-1129.
- Zhang B, Schmidt B. Do we measure the right endpoints? A systematic review of primary outcomes in recent neonatal randomized clinical trials. J of Pediatr, 2001; 138:76-80.
- Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts R, Saigal S, Solimano A, Vincer M, Wright L, for the TIPP investigators. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med, 2001; 344:1966-1972.
- Schmidt B, Gillie P, Caco C, Roberts J, Roberts R. Do sick newborn infants benefit from participation in a randomized clinical trial? J Pediatr 1999;134:151-155.